Wed, April 25, 2012
Tue, April 24, 2012
Mon, April 23, 2012
Sun, April 22, 2012
Sat, April 21, 2012
Fri, April 20, 2012
Thu, April 19, 2012
Wed, April 18, 2012
Tue, April 17, 2012
Mon, April 16, 2012
Sun, April 15, 2012
[ Sun, Apr 15th 2012 ] - Market Wire
DaVita Announces CFO Transition
Sat, April 14, 2012
Fri, April 13, 2012
Thu, April 12, 2012

Access Pharmaceuticals, Inc. to Present at Taglich Brothers 9th Annual Small Cap Equity Conference


//health-fitness.news-articles.net/content/2012/ .. hers-9th-annual-small-cap-equity-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


April 19, 2012 09:30 ET

Access Pharmaceuticals, Inc. to Present at Taglich Brothers 9th Annual Small Cap Equity Conference

NEW YORK, NY--(Marketwire - Apr 19, 2012) - [ Taglich Brothers, Inc. ] is pleased to announce that Jeffrey B. Davis, CEO of Access Pharmaceuticals, Inc. (OTCBB: [ ACCP ]) will be presenting at our 9th Annual Small Cap Equity Conference May 1, 2012. The Conference will take place at the New York Athletic Club, New York City. To request additional information or to [ register ], contact [ Taglich Brothers ] at 212-779-2971 or visit [ www.taglich.com ].

About Taglich Brothers
[ Taglich Brothers, Inc ]. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

About Access Pharmaceuticals, Inc.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include [ MuGard™ ] ([ www.MuGard.com ]), which has received FDA marketing clearance for the management of patients with mucositis, [ ProLindac™, ] a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and [ Thiarabine ]™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including [ CobaCyte™-mediated targeted delivery ] and [ CobOral-oral drug delivery ], its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at [ www.accesspharma.com ].



Publication Contributing Sources